SS
ITOS

Steve Schonfeld’s iTeos Therapeutics ITOS Stock Holding History

Steve Schonfeld’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-57,877
Closed -$346K – 2274
2025
Q1 		$346K Sell
57,877
-5,100
-8% -$37.4K ﹤0.01% 1732
2024
Q4 		$484K Sell
62,977
-5,266
-8% -$45.2K ﹤0.01% 1424
2024
Q3 		$697K Buy
+68,243
New +$1.04M ﹤0.01% 1290
2022
Q3 		– Sell
-51,430
Closed -$1.06M – 3071
2022
Q2 		$1.06M Buy
51,430
+24,542
+91% +$582K 0.01% 1000
2022
Q1 		$865K Buy
+26,888
New +$977K 0.01% 1066

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Steve Schonfeld's ITOS Position: Q2 2025 in Review

Steve Schonfeld sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 57,877 shares — an estimated $346K sold.

Steve Schonfeld first reported a position in ITOS in Q1 2022 and held it in 5 quarters. The position peaked at $1.06M in Q2 2022. 137 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • Steve Schonfeld reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Steve Schonfeld sold 57,877 iTeos Therapeutics shares in Q2 2025, an estimated $346K.
  • Steve Schonfeld first reported a position in iTeos Therapeutics in Q1 2022 and held it in 5 quarters.
  • Steve Schonfeld's iTeos Therapeutics position peaked at $1.06M in Q2 2022.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.